Stayble Therapeutics AB (STABL) AI Stock Analysis

• Market Cap: kr13.45M
• Dividend Yield: N/A
• Average Volume (3M): 378.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: N/A
• EPS Growth: 64.02%
• Country: SE
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 64,359,795
• 10 Day Avg. Volume: 398,578
• 30 Day Avg. Volume: 378,512
• PEG Ratio: 0.02
• Price to Book (P/B): 2.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: kr0.19 ▼(-22.92% Downside)

The score is held down primarily by weak financial performance (minimal revenue, large losses, and ongoing cash burn) and bearish technical trend signals (price below key moving averages with negative MACD). Valuation offers limited support because the company is loss-making (negative P/E) and no dividend yield is available.

Positive Factors

Balance-sheet leverage

Modest debt relative to equity (~0.10x) reduces near-term financing strain and provides greater flexibility for a cash-burning biotech. This lowers default risk versus highly leveraged peers and lengthens runway for R&D execution before urgent refinancing needs arise.

Improving cash burn trend

Operating and free cash flow remain negative but the meaningful reduction in burn versus 2023–2024 implies tighter cost control or lower spend. A sustained lower burn rate extends the company’s runway and increases odds of reaching clinical milestones before large new financing rounds.

Focused clinical program

A single, clearly defined program (STA363) targeting underlying disc pathology addresses an unmet, structural market need in chronic low back pain. Focused pipelines can concentrate resources, making trial design, regulatory strategy, and eventual commercialization efforts more coherent and durable if clinical efficacy is proven.

Negative Factors

Very limited revenue

Almost no commercial revenue (TTM 22k) leaves the company fully dependent on financing and R&D success. The lack of diversified revenue streams makes long-term sustainability contingent on trial outcomes and capital markets, increasing binary risk over the next 2–6 months and beyond.

Negative cash generation

Persistent negative operating and free cash flow (-6.8M TTM) indicates ongoing cash burn and that operational activities do not cover expenditures. Without durable cash generation, the company will likely require external funding, creating execution and dilution risk that can impair long-term shareholder value.

Shrinking equity and negative ROE

Material equity contraction and very negative ROE (~-103%) reflect accumulated losses and capital erosion. This signals ongoing dilution and financing vulnerability: if losses persist, management will likely need to raise capital, diluting existing shareholders and increasing financial risk over time.

Stayble Therapeutics AB Business Overview & Revenue Model

Company Description

Stayble Therapeutics AB (STABL) is a clinical-stage pharmaceutical company based in Sweden that focuses on developing innovative treatments for degenerative disc disease and other musculoskeletal disorders. The company is primarily engaged in the research and development of non-surgical therapies that address the underlying causes of chronic back pain, offering potential relief and improved quality of life for patients.

How the Company Makes Money

Stayble Therapeutics AB generates revenue through the development and eventual commercialization of its proprietary treatment solutions for degenerative disc disease. The company primarily invests in clinical trials and research to bring its products to market, aiming to license its technologies to larger pharmaceutical companies upon successful trial results. Significant revenue streams are expected to arise from licensing agreements, milestone payments, and royalties from sales of approved therapies. Partnerships with research institutions and healthcare organizations may also contribute to its earnings by bolstering research capabilities and expanding market reach.

Stayble Therapeutics AB Financial Statement Overview

Summary

Development-stage profile with minimal TTM revenue (22k) and large losses (EBIT -4.9M; net loss -8.4M) plus negative operating/free cash flow (-6.8M). Offsetting positives are modest leverage (~0.10x debt-to-equity) and improving loss/burn versus 2023–2024, but shrinking equity and high negative ROE (~-103%) keep financing risk elevated.

Income Statement

TTM (Trailing-Twelve-Months) revenue remains very small (22k), while losses are still substantial (EBIT -4.9M; net loss -8.4M), keeping profitability deeply negative. The main positive is a clear reduction in annual losses versus 2023–2024, suggesting tighter cost control or a lower spend rate, but the business is still pre-commercial with limited revenue visibility.

Balance Sheet

Leverage is modest with debt roughly 0.10x equity in TTM (Trailing-Twelve-Months), which reduces financial risk relative to many cash-burning peers. However, equity has contracted materially from 2021 to TTM as accumulated losses have been absorbed, and returns to shareholders remain strongly negative (TTM return on equity about -103%), signaling ongoing dilution/financing risk if losses persist.

Cash Flow

Cash burn remains the key issue: TTM (Trailing-Twelve-Months) operating and free cash flow are both -6.8M, and cash flow has not yet turned the corner into sustainably improving trends. A positive is that the burn rate is meaningfully lower than 2023–2024 levels, but with continued negative cash generation, the company likely depends on external funding until commercialization.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	22.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	22.00K	-148.21K	0.00	0.00	0.00	0.00
EBITDA	-6.49M	-12.22M	309.41K	-24.50M	-12.03M	-15.09M
Net Income	-8.42M	-12.42M	-23.74M	-24.53M	-12.04M	-15.49M
Balance Sheet
Total Assets	9.90M	9.26M	21.70M	19.15M	43.64M	18.00M
Cash, Cash Equivalents and Short-Term Investments	3.80M	2.19M	14.08M	12.85M	37.47M	10.87M
Total Debt	850.00K	850.00K	850.00K	850.00K	850.00K	850.00K
Total Liabilities	1.44M	2.38M	5.19M	3.87M	3.83M	2.45M
Stockholders Equity	8.46M	6.87M	16.51M	15.28M	39.81M	15.55M
Cash Flow
Free Cash Flow	-6.78M	-14.67M	-23.54M	-24.89M	-9.63M	-23.98M
Operating Cash Flow	-6.78M	-14.67M	-23.54M	-24.89M	-9.63M	-23.98M
Investing Cash Flow	0.00	0.00	0.00	1.00K	-1.00K	0.00
Financing Cash Flow	6.99M	2.78M	24.96M	1.00K	36.15M	31.19M

Stayble Therapeutics AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STABL, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.22, above the 50-day MA of 0.23, and below the 200-day MA of 0.33, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.51 is Neutral, neither overbought nor oversold. The STOCH value of 72.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:STABL.

Stayble Therapeutics AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FLUI	46 Neutral	kr11.68M	-1.18	-45.97%	―	―	―
LARK	43 Neutral	kr43.76M	-0.98	―	8.47%	-94.12%	-25.83%
STABL	42 Neutral	kr13.45M	-1.23	-91.33%	―	―	64.02%
LIDDS	41 Neutral	kr2.43M	-0.42	-132.58%	―	―	86.26%